13.1% Below Target

Quest Diagnostics Incorporated (DGX) has a consensus 12-month price target of $220.57, implying 13.1% upside from $195. The 34 analysts covering DGX see moderate appreciation potential.

DGX has a consensus rating of "Hold" based on 34 Wall Street analysts. The rating breakdown is mixed, with 18 Hold ratings making up the largest segment. The consensus 12-month price target of $220.57 implies 13.1% upside from current levels.

With a forward P/E of 18.1438x, DGX trades at a relatively low valuation. The consensus target of $220.57 implies 13.1% appreciation, suggesting meaningful undervaluation.

The most bullish Wall Street analyst has a price target of $235 for DGX, while the most conservative target is $210. The consensus of $220.57 represents the median expectation. Our quantitative valuation model projects a bull case target of $322 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

DGX is heavily covered by Wall Street, with 34 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 13 have Buy ratings, 18 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month DGX stock forecast based on 34 Wall Street analysts shows a consensus price target of $220.57, with estimates ranging from $210 (bear case) to $235 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $245, with bear/bull scenarios of $154/$322.

Our quantitative valuation model calculates DGX's fair value at $245 (base case), with a bear case of $154 and bull case of $322. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.

DGX trades at a forward P/E ratio of 18.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 22.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Wall Street analysts are optimistic on DGX, with a "Hold" consensus rating and $220.57 price target (13.1% upside). 13 of 34 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

DGX analyst price targets range from $210 to $235, a 11% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $220.57 consensus represents the middle ground. Our model's $154-$322 range provides an independent fundamental perspective.